Search

Author/Creator Mukherjee, Neelam

1. 719 CD122-directed interleukin-2 complexes and αPD-L1 differentially require innate and adaptive immunity to treat local and metastatic bladder cancer. (10th December 2020)

Authors:
Reyes, Ryan; Deng, Yilun; Zhang, Deyi; Ji, Niannian; Mukherjee, Neelam; Wheeler, Karen; Gupta, Harshita; Kancharla, Aravind; Garcia, Myrna; Kornepati, Anand; Svatek, Robert; Curiel, Tyler
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8(2020)Supplement 3
Page Start:
A430
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 719 CD122-directed interleukin-2 complexes and αPD-L1 differentially require innate and adaptive immunity to treat local and metastatic bladder cancer. (9th November 2020)

Authors:
Reyes, Ryan; Deng, Yilun; Zhang, Deyi; Ji, Niannian; Mukherjee, Neelam; Wheeler, Karen; Gupta, Harshita; Kancharla, Aravind; Garcia, Myrna; Kornepati, Anand; Svatek, Robert; Curiel, Tyler
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 8(2020)Supplement 3
Page Start:
A761
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation. Issue 4 (13th April 2021)

Authors:
Reyes, Ryan Michael; Deng, Yilun; Zhang, Deyi; Ji, Niannian; Mukherjee, Neelam; Wheeler, Karen; Gupta, Harshita B; Padron, Alvaro S; Kancharla, Aravind; Zhang, Chenghao; Garcia, Myrna; Kornepati, Anand V R; Boyman, Onur; Conejo-Garcia, Jose R; Svatek, Robert S; Curiel, Tyler J
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 9:Issue 4(2021)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. CD122-targeted interleukin-2 and αPD-L1 treat bladder cancer and melanoma via distinct mechanisms, including CD122-driven natural killer cell maturation. (1st January 2021)

Authors:
Reyes, Ryan M; Zhang, Chenghao; Deng, Yilun; Ji, Niannian; Mukherjee, Neelam; Padron, Alvaro S; Clark, Curtis A; Svatek, Robert S; Curiel, Tyler J
Journal:
Oncoimmunology
Issue:
Volume 10:Number 1(2021)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. KLRF1, a novel marker of CD56bright NK cells, predicts improved survival for patients with locally advanced bladder cancer. (29th December 2022)

Authors:
Mukherjee, Neelam; Ji, Niannian; Tan, Xi; Chen, Chun‐Liang; Noel, Onika D. V.; Rodriguez‐Padron, Maria; Lin, Chun‐Lin; Alonzo, David G.; Huang, Tim H.; Svatek, Robert S.
Journal:
Cancer medicine
Issue:
Volume 12:Number 7(2023)
Page Start:
8970
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Percutaneous BCG enhances innate effector antitumor cytotoxicity during treatment of bladder cancer: a translational clinical trial. (3rd August 2019)

Authors:
Ji, Niannian; Mukherjee, Neelam; Morales, Edwin E.; Tomasini, Maggie E.; Hurez, Vincent; Curiel, Tyler J.; Abate, Getahun; Hoft, Dan F.; Zhao, Xiang-Ru; Gelfond, Jon; Maiti, Sourindra; Cooper, Laurence J.N.; Svatek, Robert S.
Journal:
Oncoimmunology
Issue:
Volume 8:Number 8(2019)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Rapamycin enhances BCG-specific γδ T cells during intravesical BCG therapy for non-muscle invasive bladder cancer: a randomized, double-blind study. Issue 3 (2nd March 2021)

Authors:
Ji, Niannian; Mukherjee, Neelam; Reyes, Ryan M; Gelfond, Jonathan; Javors, Martin; Meeks, Joshua J.; McConkey, David J; Shu, Zhen-Ju; Ramamurthy, Chethan; Dennett, Ryan; Curiel, Tyler J; Svatek, Robert S
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 9:Issue 3(2021)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗